Identification

Name
St. John's Wort
Accession Number
DB01323
Type
Small Molecule
Groups
Approved, Investigational, Nutraceutical
Description
Not Available
Synonyms
  • Common st johnswort flowering top
  • Common st. john's wort flowering top
  • Common st. john's wort herb
  • Common st. johnswort flowering top
  • Guanyejinsitao
  • Hyperici herba
  • Hypericum nachitschevanicum flowering top
  • Hypericum perforatum flowering top
  • Hypoxis hemerocallidea root extract
  • Klamath weed flowering top
  • Klamathweed flowering top
  • Saint johns wort
  • St john's wort
  • St Johns Wort
  • St. john’s wort
  • St. johns wort
  • St. johnswort flowering top
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ethical Herbal's ST. John's WortTablet900 mgOralAshbury Research CorporationNot applicableNot applicableCanada
Ethical Herbals ST.john's WortTablet300 mgOralAshbury Research CorporationNot applicableNot applicableCanada
HypericumCapsule300 mgOralThorne Research Inc.Not applicableNot applicableCanada
KiraTablet180 mgOralLichtwer Healthcare Gmbh & Co KgNot applicableNot applicableCanada
Kira (extract Li 160)Tablet300 mgOralLichtwer Healthcare Gmbh & Co KgNot applicableNot applicableCanada
Quanterra SpiritTablet1500 mgOralWarner Lambert Canada Inc.Not applicableNot applicableCanada
ST. John's Wort FormulaCapsule1045 mgOralEnrich InternationalNot applicableNot applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ethical Herbals ST. John's WortTablet150 mgOralAshbury Research CorporationNot applicableNot applicableCanada
Ethical Herbals ST. John's WortTablet300 mgOralAshbury Research CorporationNot applicableNot applicableCanada
Felis Forte Capsules 425mgCapsule425 mgOralRhoxalpharma IncNot applicableNot applicableCanada
Felis Tablets 250mgTablet250 mgOralRhoxalpharma IncNot applicableNot applicableCanada
ST. John's WortCapsule300 mgOralSwiss Herbal Remedies Ltd.1998-02-202008-08-15Canada
ST. John's WortCapsule1050 mgOralWn Pharmaceuticals Ltd.1998-12-152006-08-08Canada
ST. John's WortCapsule1500 mgOralBioprint Laboratories Ltd2000-06-082001-07-31Canada
ST. John's WortCapsule750 mgOralPharmavite1999-01-202004-07-20Canada
ST. John's WortCapsule300 mgOralNew Vision Nutritionals Company1998-10-012002-11-20Canada
ST. John's WortCapsule1500 mgOralSisu Inc.1998-02-112007-07-20Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Nite-capsSt. John's Wort (20 mg) + Hops (40 mg) + Valerian (40 mg)CapsuleOralFlora Manufacturing And Distributing Ltd.1991-12-312002-09-10Canada
S. R. FormulaSt. John's Wort (200 mg) + Valerian (133.2 mg)LiquidOralMorinda Canada2002-01-142006-07-12Canada
Categories
UNII
UFH8805FKA
CAS number
84082-80-4
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be increased when combined with St. John's Wort.
(S)-WarfarinThe metabolism of (S)-Warfarin can be increased when combined with St. John's Wort.
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with St. John's Wort.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when St. John's Wort is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of serotonin syndrome can be increased when St. John's Wort is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineThe risk or severity of serotonin syndrome can be increased when St. John's Wort is combined with 3,4-Methylenedioxyamphetamine.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be increased when combined with St. John's Wort.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of serotonin syndrome can be increased when St. John's Wort is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be increased when combined with St. John's Wort.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when St. John's Wort is combined with 4-Methoxyamphetamine.
Food Interactions
Not Available

References

Synthesis Reference

Trevor Percival Castor, Theodore Abraham Tyler, Richard Joseph Student, "Methods for making Hypericum fractions and St. John's Wort products." U.S. Patent US6291241, issued December, 1998.

US6291241
General References
  1. Lecrubier Y, Clerc G, Didi R, Kieser M: Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002 Aug;159(8):1361-6. [PubMed:12153829]
  2. Randlov C, Mehlsen J, Thomsen CF, Hedman C, von Fircks H, Winther K: The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study. Phytomedicine. 2006 Mar;13(4):215-21. Epub 2006 Jan 19. [PubMed:16423519]
  3. Authors unspecified: Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002 Apr 10;287(14):1807-14. [PubMed:11939866]
External Links
PubChem Substance
46507869
PharmGKB
PA164924486
Drugs.com
Drugs.com Drug Page
Wikipedia
St_John%27s_wort
ATC Codes
N06AX25 — Hyperici herba
AHFS Codes
  • 92:01.00* — Herbs and Natural Products

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableVA Drug Interactions [VA Drug Interaction]1
1CompletedPreventionHepatitis C Viral Infection1
2CompletedTreatmentAnxiety Disorders / Major Depressive Disorder (MDD)1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
2CompletedTreatmentIrritable Bowel Syndrome (IBS)1
2CompletedTreatmentNicotine Dependence / Smoking1
2CompletedTreatmentObsessive Compulsive Disorder (OCD)1
2CompletedTreatmentPhobic Disorders1
2TerminatedSupportive CareCancer, Breast / Menopausal Hot Flushes1
2, 3CompletedTreatmentAnxiety Disorders / Mental Health1
3CompletedTreatmentAtypical Depression1
3CompletedTreatmentRaynaud's Disease1
3RecruitingDiagnosticPeritoneal Carcinomatosis1
3WithdrawnTreatmentAdult Solid Tumor / Cancer, Breast / Head and Neck Carcinoma / Kidney and Urinary Cancer / Male Reproductive Cancer / Thorax and Respiratory Cancer1
4CompletedDiagnosticPain NOS1
4CompletedTreatmentHealthy Volunteers1
4TerminatedTreatmentDepression1
Not AvailableCompletedNot AvailableHealthy Volunteers / Moods Disorders1
Not AvailableCompletedNot AvailableVA Drug Interactions [VA Drug Interaction]1
Not AvailableCompletedTreatmentContraception1
Not AvailableCompletedTreatmentDepression1
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)1
Not AvailableWithdrawnTreatmentAcute Coronary Syndromes (ACS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Guna Inc.
  • Pekana Naturheilmittel GmbH
  • Weleda Inc.
Dosage forms
FormRouteStrength
TabletOral900 mg
TabletOral150 mg
TabletOral300 mg
CapsuleOral425 mg
TabletOral250 mg
TabletOral180 mg
CapsuleOral
TabletOral1500 mg
LiquidOral
CapsuleOral1050 mg
CapsuleOral1500 mg
CapsuleOral750 mg
TabletOral500 mg
LiquidOral1000 mg
CapsuleOral1045 mg
CapsuleOral1320 mg
LiquidOral1 g
CapsuleOral300 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Wenk M, Todesco L, Krahenbuhl S: Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol. 2004 Apr;57(4):495-9. [PubMed:15025748]
  2. Hokkanen J, Tolonen A, Mattila S, Turpeinen M: Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci. 2011 Feb 14;42(3):273-84. doi: 10.1016/j.ejps.2010.12.002. Epub 2010 Dec 17. [PubMed:21168483]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Hokkanen J, Tolonen A, Mattila S, Turpeinen M: Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci. 2011 Feb 14;42(3):273-84. doi: 10.1016/j.ejps.2010.12.002. Epub 2010 Dec 17. [PubMed:21168483]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Hokkanen J, Tolonen A, Mattila S, Turpeinen M: Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci. 2011 Feb 14;42(3):273-84. doi: 10.1016/j.ejps.2010.12.002. Epub 2010 Dec 17. [PubMed:21168483]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K: St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000 Dec;68(6):598-604. [PubMed:11180019]

Drug created on June 30, 2007 11:20 / Updated on December 09, 2018 01:12